Quince Therapeutics, Inc. announced on July 21, 2023, the Company Board of Directors approved the appointment of Luca Benatti to serve as a director of the Company, contingent and effective upon the closing of the EryDel Acquisition. On July 24, 2023, the Company announced that Karen Smith, Chief Medical Officer of the Company, would be leaving the Company, effective September 1, 2023. Ms. Smith?s departure is not the result of any disagreement with the Company on any matter relating to the Company?s financial operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | +2.91% | +0.95% | +0.95% |
Apr. 01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 26 | Transcript : Quince Therapeutics, Inc. - Special Call |
1st Jan change | Capi. | |
---|---|---|
+0.95% | 45.81M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics, Inc. Announces Board and Executive Changes